Table 2.
Retrospective analysis of clinical and imaging features of all patients.
| Parameter | Non-remission | Remission | P-value |
|---|---|---|---|
| Age (Median (IQR)) | 58.0 years (27.0) | 61.5 years (19.0) | 0.317 |
| Gender (N) | 0.089 | ||
| Male | 33 | 117 | |
| Female | 47 | 103 | |
| Weight | 0.066 | ||
| BMI < 25.0 | 28 | 104 | |
| BMI ≥ 25.0 | 52 | 116 | |
| Tumor origin | 0.004* | ||
| Breast cancer | 31 | 47 | |
| Lung cancer | 49 | 173 | |
| Steroid history | 0.068 | ||
| Yes | 71 | 209 | |
| No | 9 | 11 | |
| Dehydrant history | 0.085 | ||
| Yes | 72 | 9 | |
| No | 8 | 211 | |
| Radiotherapy | 0.069 | ||
| Yes | 54 | 172 | |
| No | 26 | 48 | |
| Operation | 0.040* | ||
| Yes | 56 | 179 | |
| No | 24 | 41 | |
| Electrolyte disorder | 0.102 | ||
| Yes | 27 | 52 | |
| No | 53 | 168 | |
| New-onset hypertension | 0.090 | ||
| Yes | 13 | 57 | |
| No | 67 | 163 | |
| BEV dose | 10.0 mg/kg (5.0) | 10.0 mg/kg (0.0) | 0.172 |
| BEV interval | 2.0 weeks (1.0) | 2.0 weeks (1.0) | 0.005* |
| BEV frequency | 4.0 times (4.0) | 3.0 times (2.0) | 0.575 |
| Tumor location | 0.215 | ||
| Frontal lobe | 16 | 62 | |
| Parietal lobe | 23 | 75 | |
| Temporal lobe | 19 | 33 | |
| Occipital lobe | 10 | 18 | |
| Polyencephalic lobe | 12 | 32 | |
| Maximum tumor diameter | 3.6 cm (0.7) | 3.5 cm (0.7) | 0.538 |
| Tumor volume | 17.1 ccm (10.0) | 15.6 ccm (9.7) | 0.383 |
| Edema volume | 26.0 ccm (19.8) | 51.0 ccm (18.8) | < 0.001* |
| Edema index | 2.7 (1.1) | 3.9 (2.2) | 0.020* |
An asterisk (*) indicates a statistically significant P value of less than 0.05.
IQR InterQuartile Range, BMI body mass index, BEV bevacizumab.